Sponsors Should Manage Adverse Event Reports To Reduce IRB Burden – Lilly
Executive Summary
Sponsors should be responsible for oversight of adverse event safety data review to reduce institutional review board burden, Lilly Project Leader Vish Watkins says
You may also be interested in...
Adverse Event Reporting In Clinical Trials Can Flow Through Sponsors – FDA
Drug trial sponsors can supervise reports of "unanticipated problems" to Institutional Review Boards under an FDA 1draft guidance on adverse event reporting
Adverse Event Reporting In Clinical Trials Can Flow Through Sponsors – FDA
Drug trial sponsors can supervise reports of "unanticipated problems" to Institutional Review Boards under an FDA 1draft guidance on adverse event reporting
FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next
HHS is planning a major overhaul of FDA's postmarketing surveillance system as the centerpiece of its next announcement about upgrades to the drug safety regulatory system